Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak

Executive Summary

As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space
Advertisement

Related Content

Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”
Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”
Bristol Pays $85 Million Upfront To Acquire Rheumatoid Arthritis Compound From Alder
Clinical Trials Disclosure Code From International Group Covers All Studies Of Life-Threatening Conditions
The New Oral MS Drugs: The Challenges in Dislodging Biologics
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR
Cephalon Launches Takeover Bid For Australian Biotech Arana
Cephalon Option To Buy Biologics Firm Ception Gets The Ball Rolling For 2009, CEO Says
Market Snapshot: Anti-TNFs Grow Despite Tough Market

Topics

Advertisement
UsernamePublicRestriction

Register

PS051712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel